Keyword: GlaxoSmithKline

GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.

GSK has the strictest sales pay rules in the industry, but it's loosening up. It will now allow specialty salespeople to take home bigger paychecks.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.

GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.

Pharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year, says annual study.

A handful of branded drug ads are using popular ‘70s light rock songs, both to aid recall and to reach older audiences with music from their youth.

GSK has data in hand that could help Trelegy move into the asthma arena—though it's not all positive.

GSK's shingles vaccine Shingrix trounced expectations, but its HIV franchise is suffering on new competition from Gilead.

After a two-and-a-half-year wait for impulse-control warnings on six dopamine drugs, a watchdog group sued to force FDA action.